CANGRELOR

Course overview

CANGRELOR, A POTENT INTRAVENOUS ANTIPLATELET AGENT, HAS BEEN APPROVED BY THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) FOR ITS USE IN SPECIFIC PATIENT POPULATIONS UNDERGOING PERCUTANEOUS CORONARY INTERVENTION (PCI). THE DRUG'S EFFICACY IN REDUCING THROMBOTIC EVENTS DURING AND AFTER PCI IS ATTRIBUTED TO ITS UNIQUE MECHANISM OF ACTION, PHARMACOKINETICS, AND PHARMACODYNAMICS. ALTHOUGH CANGRELOR IS GENERALLY WELL TOLERATED, HEALTHCARE PROFESSIONALS MUST BE AWARE OF THE POTENTIAL ADVERSE DRUG REACTIONS (ADRS), DRUG INTERACTIONS, CONTRAINDICATIONS, AND MANAGING OVERDOSE RELATED TO CANGRELOR. THIS THERAPEUTIC REVIEW AIMS TO PROVIDE AN IN-DEPTH ANALYSIS OF CANGRELOR, ENCOMPASSING ITS INDICATIONS, FDA APPROVAL, OFF-LABEL USES, MECHANISM OF ACTION, PHARMACOKINETICS, PHARMACODYNAMICS, AND ADRS. MOREOVER, THIS ACTIVITY ALSO HIGHLIGHTS THE CRUCIAL ROLE OF INTERPROFESSIONAL COLLABORATION IN ENHANCING PATIENT OUTCOMES.